Business Context and Reporting Period
Company: Manhattan Pharmaceuticals, Inc. (Note: Request metadata listed "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: A development-stage biopharmaceutical company focused on acquiring, developing, and commercializing treatments for underserved populations. The company has no product revenues and relies on financing and joint ventures. Key assets include a joint venture for Hedrin (head lice treatment) and a topical gel for psoriasis. Several other programs (Oleoyl-estrone, Propofol Lingual Spray, Altoderm, Altolyn) were discontinued in 2007 or early 2009 due to clinical failures or lack of funding.
Key Financial Metrics
| Metric | 2008 | 2007 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,268,858) | $(12,032,252) |
| Operating Expenses | $4,412,702 | $12,143,957 |
| Cash and Cash Equivalents (Year End) | $106,023 | $649,686 |
| Working Capital Deficit | $(612,000) | $(1,006,000) |
| Accumulated Deficit (Inception to 2008) | $(59,267,928) | $(54,999,070) |
| Debt (Secured Notes) | $1,244,107 (Net of discounts/costs) | $0 |
Note: The company reported $144,000 in "Other Income" for 2008, primarily from management fees earned from the Hedrin Joint Venture.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 64% ($7.7 million) compared to 2007. This was driven by a 79% drop in Research & Development (R&D) expenses and a 28% drop in General & Administrative (G&A) expenses, largely due to the discontinuation of several drug programs and reduced milestone payments.
- Liquidity Deterioration: Cash and cash equivalents declined by approximately 84% ($544,000) during the year. The company ended 2008 with only $106,023 in unrestricted cash.
- Debt Financing: The company issued Secured 10% Notes ($70,000) and Secured 12% Notes (approx. $1.3 million principal) in late 2008 to fund operations, creating a new debt obligation not present in 2007.
- Joint Venture Milestone: The company received approximately $2.7 million in cash proceeds from the Hedrin Joint Venture (JV) in 2008, which partially offset operating cash burn.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
Management and auditors have expressed substantial doubt about the company's ability to continue as a going concern. The company has incurred losses since inception and expects to continue incurring losses through at least 2009. Continued operations depend on raising additional funds through equity/debt financing or generating cash flow from the Hedrin JV.
Outlook and Guidance
- Capital Needs: Management believes current resources plus proceeds received in early 2009 (approx. $860,000 from JV and notes) are sufficient to fund operations through 2009. Additional financing is required for 2010 and beyond.
- Product Pipeline:
- Hedrin: Classified as a Class III medical device by the FDA in January 2009, requiring a Premarket Approval (PMA) and at least one clinical trial. Development costs are now borne by the Hedrin JV.
- Psoriasis Gel: The active ingredient (PTH 1-34) failed Phase 2a trials. The company is exploring the vehicle (GEL) as a potential OTC product.
- Discontinued: Altoderm and Altolyn were discontinued in March 2009 due to lack of funds and inconclusive data.
Material Risks and Contingencies
- Legal Proceedings (Swiss Pharma): The company lost an arbitration in Switzerland regarding a clinical trial dispute. The award totaled approximately $646,000 (including penalties and legal fees). The company lacks sufficient cash to satisfy this award. Swiss Pharma has petitioned a New York court to confirm the award and enter judgment.
- Stock Volatility and Delisting: The company voluntarily delisted from the American Stock Exchange (AMEX) in March 2008 due to non-compliance with listing standards and now trades on the OTC Bulletin Board. Stock price ranged from $0.007 to $0.23 in 2008.
- Regulatory Risk: No products have received FDA approval. Future clinical trials are expensive and uncertain.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $106,023 cash balance on hand plus the $860,000 in subsequent 2009 proceeds to cover operating expenses through 2009.
- Swiss Pharma Judgment: Monitor the status of the New York court proceedings to confirm the $646,000 arbitration award, which poses an immediate liquidity threat.
- Hedrin JV Funding: Confirm the receipt of the $500,000 milestone payment from the Hedrin JV (triggered by FDA Class III classification) and the JV's ability to fund the required PMA clinical trials.
- Debt Covenants: Review the terms of the Secured 12% Notes, which are secured by nearly all company assets (excluding the Hedrin JV interest) and include warrants that may cause significant dilution.
- Management Retention: Verify the status of employment agreements for the CEO and CFO, which were subject to salary reductions based on financing milestones.